Hospital
North Broward Hospital District
North Broward Hospital District was paid $37.11M by Medicaid between Jan 2018 and Dec 2024, across 370 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoNORTH BROWARD HOSPITAL DISTRICT
FORT LAUDERDALE, FL 33316
FORT LAUDERDALE, FL 33316
33aNPI1285662239assigned 06/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.11M
24GClaims1,384,000
24DCodes billed370
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#4 of 163
Median peer was paid$4.77M
This provider vs. median7.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BERT, ALISA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 117,274 | $3.54M | |
| 2019 | 280,058 | $6.20M | |
| 2020 | 219,218 | $3.92M | |
| 2021 | 262,705 | $5.56M | |
| 2022 | 275,819 | $8.46M | |
| 2023 | 155,696 | $6.20M | |
| 2024incomplete | 73,230 | $3.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 71,763 | 65,439 | $6.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 61,219 | 52,623 | $5.66M |
| 36415 | Collection of venous blood by venipuncture | 5.5% | 93,267 | 63,135 | $2.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 25,740 | 20,886 | $1.85M |
| 59899 | 3.6% | 5,456 | 3,997 | $1.34M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 15,260 | 14,089 | $1.27M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 10,317 | 8,632 | $1.17M |
| 80053 | Comprehensive metabolic panel | 3.0% | 78,346 | 60,569 | $1.12M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.7% | 13,007 | 10,278 | $1.00M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 4,981 | 4,323 | $797K |
| G0378 | Hospital observation service, per hour | 2.0% | 23,523 | 11,233 | $731K |
| 87631 | 1.8% | 4,933 | 4,718 | $666K |
358 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 11,502 | $639K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 109,694 | $540K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 1.4% | 1,784 | $509K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 6,314 | $398K |
| 59025 | Fetal non-stress test | <1% | 3,394 | $371K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 24,479 | $361K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 7,836 | $339K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,839 | $324K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,602 | $310K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,065 | $294K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,258 | $251K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,649 | $242K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,731 | $240K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 474 | $238K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,599 | $232K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 21,382 | $227K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,690 | $219K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,751 | $201K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,967 | $190K |
| 81001 | <1% | 41,607 | $184K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,176 | $178K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,718 | $177K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,804 | $153K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 213 | $147K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,006 | $134K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,413 | $122K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,474 | $116K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,775 | $114K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,246 | $114K |
| 87070 | <1% | 8,757 | $107K | |
| 36430 | <1% | 2,265 | $107K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,062 | $101K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,559 | $100K |
| 54160 | <1% | 107 | $100K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,574 | $100K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 898 | $85K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,342 | $85K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,849 | $84K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,076 | $83K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,611 | $82K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 502 | $80K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,898 | $78K |
| 86900 | <1% | 13,786 | $76K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 10,200 | $76K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,600 | $73K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,950 | $73K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,326 | $71K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,899 | $70K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 875 | $69K |
| 93970 | <1% | 1,174 | $69K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,940 | $69K |
| 85610 | <1% | 13,376 | $68K | |
| 76775 | <1% | 1,288 | $68K | |
| 84702 | <1% | 9,611 | $67K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 323 | $67K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 15,259 | $67K |
| 86901 | <1% | 13,780 | $67K | |
| 87340 | <1% | 6,870 | $63K | |
| 88185 | <1% | 4,428 | $61K | |
| 74018 | <1% | 5,374 | $61K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,074 | $60K |
| 85730 | <1% | 10,491 | $60K | |
| 86592 | <1% | 7,400 | $58K | |
| A4301 | Implantable access total catheter, port/reservoir (e.g., venous, arterial, epidural, subarachnoid, peritoneal, etc.) | <1% | 1,864 | $57K |
| 76641 | <1% | 1,179 | $56K | |
| 54161 | <1% | 100 | $56K | |
| 97161 | <1% | 1,536 | $56K | |
| 70486 | <1% | 823 | $56K | |
| 86703 | <1% | 6,641 | $56K | |
| 84436 | <1% | 432 | $55K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,418 | $53K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 746 | $52K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 5,253 | $51K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 533 | $50K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,627 | $50K |
| 81025 | <1% | 7,640 | $50K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,960 | $50K |
| 88142 | <1% | 4,197 | $48K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,702 | $47K |
| 93971 | <1% | 1,784 | $45K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,484 | $45K |
| 70491 | <1% | 135 | $44K | |
| 97010 | <1% | 453 | $44K | |
| 86850 | <1% | 9,197 | $44K | |
| 87210 | <1% | 3,208 | $41K | |
| 86885 | <1% | 3,990 | $40K | |
| 86762 | <1% | 4,200 | $39K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,848 | $38K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 316 | $37K |
| 85660 | <1% | 5,128 | $37K | |
| 84484 | <1% | 13,411 | $35K | |
| 82677 | <1% | 2,028 | $34K | |
| 83735 | <1% | 7,757 | $34K | |
| 82950 | <1% | 3,206 | $31K | |
| 83690 | <1% | 12,970 | $31K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,977 | $30K |
| 87077 | <1% | 2,750 | $29K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 126 | $28K |
| 83020 | <1% | 3,601 | $28K | |
| 82105 | <1% | 2,383 | $28K | |
| 12011 | <1% | 437 | $28K | |
| P9051 | Whole blood or red blood cells, leukocytes reduced, cmv-negative, each unit | <1% | 1,511 | $27K |
| 73564 | <1% | 2,196 | $27K | |
| 96415 | <1% | 474 | $26K | |
| 73030 | <1% | 1,833 | $26K | |
| 72131 | <1% | 1,007 | $26K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,200 | $25K |
| 96417 | <1% | 604 | $25K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,854 | $25K |
| 93975 | <1% | 392 | $24K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,115 | $23K |
| 87420 | <1% | 1,441 | $23K | |
| 73610 | <1% | 1,754 | $22K | |
| 73630 | <1% | 2,265 | $22K | |
| 87486 | <1% | 1,528 | $22K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 373 | $22K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 125 | $22K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,523 | $21K |
| 73130 | <1% | 1,643 | $21K | |
| 80061 | Lipid panel | <1% | 5,169 | $21K |
| 86336 | <1% | 2,022 | $20K | |
| 82550 | <1% | 6,076 | $18K | |
| 76801 | <1% | 2,204 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,181 | $18K |
| 87040 | <1% | 6,066 | $17K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,437 | $17K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,607 | $17K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 262 | $16K |
| 84703 | <1% | 10,132 | $16K | |
| 73110 | <1% | 1,242 | $16K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 66 | $15K |
| 93886 | <1% | 120 | $14K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 355 | $14K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 305 | $14K |
| 83880 | <1% | 3,909 | $13K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,671 | $13K |
| 84100 | <1% | 3,191 | $13K | |
| 96523 | <1% | 423 | $13K | |
| 86902 | <1% | 836 | $13K | |
| 10060 | <1% | 362 | $13K | |
| 88184 | <1% | 1,882 | $13K | |
| 76536 | <1% | 235 | $13K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 168 | $13K |
| 93976 | <1% | 776 | $12K | |
| 87186 | <1% | 4,032 | $12K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 82 | $12K |
| 88304 | <1% | 1,043 | $12K | |
| 84439 | <1% | 1,637 | $11K | |
| 74022 | <1% | 2,135 | $11K | |
| 86923 | <1% | 1,784 | $11K | |
| 73502 | <1% | 1,112 | $11K | |
| 86140 | <1% | 6,981 | $10K | |
| 73090 | <1% | 767 | $10K | |
| 82728 | <1% | 3,834 | $9K | |
| 72100 | <1% | 995 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 98 | $9K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,214 | $8K |
| 73560 | <1% | 725 | $8K | |
| 87536 | <1% | 1,126 | $8K | |
| 87088 | <1% | 2,739 | $8K | |
| 82274 | <1% | 652 | $8K | |
| 12001 | <1% | 178 | $8K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,129 | $7K |
| 82378 | <1% | 1,409 | $7K | |
| 83605 | <1% | 2,249 | $7K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $7K |
| 87045 | <1% | 389 | $6K | |
| 73590 | <1% | 1,011 | $6K | |
| A9270 | Non-covered item or service | <1% | 2,806 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,762 | $6K |
| J3490 | Unclassified drugs | <1% | 1,487 | $6K |
| 77080 | <1% | 163 | $6K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,647 | $6K |
| 83615 | <1% | 2,811 | $6K | |
| 88313 | <1% | 1,181 | $6K | |
| 71250 | <1% | 156 | $6K | |
| 93017 | <1% | 248 | $6K | |
| 87205 | <1% | 1,380 | $6K | |
| 96376 | <1% | 2,491 | $5K | |
| 80329 | <1% | 482 | $5K | |
| 84550 | <1% | 1,241 | $5K | |
| 82607 | <1% | 1,672 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,011 | $5K |
| 83540 | <1% | 1,484 | $5K | |
| 82947 | <1% | 475 | $4K | |
| 85651 | <1% | 1,767 | $4K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,015 | $4K |
| 84156 | <1% | 914 | $4K | |
| 85046 | <1% | 8,347 | $4K | |
| 82951 | <1% | 315 | $4K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 75 | $4K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 723 | $4K |
| 88312 | <1% | 1,106 | $4K | |
| 72110 | <1% | 334 | $4K | |
| 87147 | <1% | 1,440 | $4K | |
| 83550 | <1% | 1,421 | $4K | |
| 76870 | <1% | 138 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,655 | $4K |
| 82803 | <1% | 801 | $4K | |
| 82570 | <1% | 1,848 | $4K | |
| 73140 | <1% | 247 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,418 | $4K |
| 87581 | <1% | 1,523 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 469 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,223 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,518 | $3K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 389 | $3K |
| 73070 | <1% | 485 | $3K | |
| 80320 | <1% | 567 | $3K | |
| 87507 | <1% | 48 | $3K | |
| 80076 | <1% | 782 | $3K | |
| 90715 | <1% | 1,281 | $3K | |
| 87081 | <1% | 76 | $2K | |
| 82952 | <1% | 317 | $2K | |
| 82248 | <1% | 1,810 | $2K | |
| 86803 | <1% | 923 | $2K | |
| 84112 | <1% | 308 | $2K | |
| 81003 | <1% | 379 | $2K | |
| 72170 | <1% | 605 | $2K | |
| 00731 | <1% | 179 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 895 | $2K |
| 84132 | <1% | 774 | $2K | |
| 88342 | <1% | 274 | $2K | |
| 84153 | <1% | 469 | $2K | |
| 85379 | <1% | 1,399 | $2K | |
| 82553 | <1% | 453 | $2K | |
| 82746 | <1% | 1,227 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 110 | $2K |
| 73100 | <1% | 46 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 205 | $2K |
| 82150 | <1% | 582 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,261 | $2K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 749 | $2K |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 38 | $2K |
| 82247 | <1% | 273 | $1K | |
| 87430 | <1% | 1,484 | $1K | |
| 93308 | <1% | 40 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 61 | $1K |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 47 | $1K |
| 86706 | <1% | 208 | $1K | |
| 73080 | <1% | 150 | $1K | |
| 87184 | <1% | 468 | $1K | |
| 36600 | <1% | 706 | $1K | |
| 85027 | <1% | 4,428 | $1K | |
| 86704 | <1% | 164 | $1K | |
| 80074 | <1% | 292 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 853 | $1K |
| 86922 | <1% | 259 | $1K | |
| 73600 | <1% | 68 | $1K | |
| 85007 | <1% | 4,207 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 91 | $986.62 |
| 86708 | <1% | 127 | $986.52 | |
| 90686 | <1% | 197 | $982.69 | |
| 72050 | <1% | 61 | $976.57 | |
| 72040 | <1% | 83 | $961.76 | |
| 86480 | <1% | 134 | $948.31 | |
| C1769 | Guide wire | <1% | 53 | $908.28 |
| 12002 | <1% | 65 | $894.64 | |
| 85384 | <1% | 628 | $881.80 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 53 | $857.39 |
| 97165 | <1% | 15 | $847.26 | |
| 82977 | <1% | 1,423 | $835.61 | |
| 73552 | <1% | 202 | $818.51 | |
| 82533 | <1% | 37 | $804.99 | |
| 72070 | <1% | 56 | $797.42 | |
| 71101 | <1% | 13 | $763.43 | |
| 29125 | <1% | 105 | $738.27 | |
| 84145 | <1% | 732 | $682.79 | |
| 87046 | <1% | 487 | $673.93 | |
| 73060 | <1% | 68 | $665.80 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 85 | $649.08 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 699 | $638.67 |
| 72128 | <1% | 201 | $630.47 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,027 | $630.38 |
| 80197 | <1% | 406 | $604.88 | |
| 86905 | <1% | 650 | $570.88 | |
| 83970 | <1% | 157 | $565.75 | |
| 82043 | <1% | 293 | $525.84 | |
| 85055 | <1% | 59 | $517.05 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 294 | $494.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 596 | $474.83 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,324 | $474.12 |
| 82010 | <1% | 528 | $391.12 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 88 | $390.06 |
| 87799 | <1% | 88 | $342.04 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 13 | $329.87 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 128 | $319.77 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 44 | $304.11 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 263 | $302.82 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 442 | $294.53 |
| 73620 | <1% | 15 | $279.38 | |
| 97116 | <1% | 179 | $267.06 | |
| 94150 | <1% | 20 | $265.15 | |
| 94664 | <1% | 782 | $263.90 | |
| 83883 | <1% | 37 | $250.76 | |
| 82784 | <1% | 225 | $229.27 | |
| 82525 | <1% | 56 | $192.00 | |
| 84630 | <1% | 111 | $179.51 | |
| 51701 | <1% | 449 | $171.67 | |
| 86300 | <1% | 42 | $155.80 | |
| 86870 | <1% | 40 | $139.43 | |
| 84403 | <1% | 26 | $135.33 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 3,652 | $102.12 |
| 87497 | <1% | 25 | $99.80 | |
| 74019 | <1% | 78 | $95.91 | |
| 84446 | <1% | 68 | $93.70 | |
| 84590 | <1% | 68 | $93.70 | |
| 00813 | <1% | 30 | $89.18 | |
| 94729 | <1% | 18 | $88.42 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 206 | $88.12 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 225 | $73.99 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 170 | $65.20 |
| 84481 | <1% | 37 | $51.08 | |
| 88300 | <1% | 73 | $36.84 | |
| 70360 | <1% | 77 | $36.77 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 555 | $28.57 |
| 96411 | <1% | 21 | $27.08 | |
| 00126 | <1% | 80 | $27.08 | |
| 85652 | <1% | 53 | $24.05 | |
| 94726 | <1% | 18 | $21.92 | |
| 86308 | <1% | 38 | $17.40 | |
| C9399 | Unclassified drugs or biologicals | <1% | 65 | $15.05 |
| 73120 | <1% | 19 | $13.54 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 29 | $13.54 |
| 83921 | <1% | 72 | $7.80 | |
| 87206 | <1% | 28 | $7.61 | |
| 82542 | <1% | 27 | $6.68 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 1,946 | $0.00 |
| 86701 | 0% | 30 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 121 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 280 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 28 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 24 | $0.00 |
| J1741 | Injection, ibuprofen, 100 mg | 0% | 126 | $0.00 |
| 88307 | 0% | 18 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 46 | $0.00 |
| 76820 | 0% | 25 | $0.00 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | 0% | 12 | $0.00 |
| 36591 | 0% | 43 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 22 | $0.00 |
| 42830 | 0% | 15 | $0.00 | |
| 96368 | 0% | 15 | $0.00 | |
| 36416 | 0% | 14 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 20 | $0.00 |
| 87425 | 0% | 13 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 110 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 161 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 60 | $0.00 |
| 96367 | 0% | 30 | $0.00 | |
| 81401 | 0% | 13 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 24 | $0.00 |
| 00920 | 0% | 97 | $0.00 | |
| 29515 | 0% | 17 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 68 | $0.00 |
| A4618 | Breathing circuits | 0% | 23 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 18 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBERT, ALISA (INTERIM CFO)
Parent organizationNORTH BROWARD HOSPITAL DISTRICT
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.